October 3, 2016

CLOSURE NOTICES
GYNECOLOGIC
GOG-0233: Termination effective July 16, 2016; Amendment 12; version date: December 22, 2014

AMENDMENTS AND UPDATES
CANCER PREVENTION & CONTROL
NRG-CC001: Amendment 1; version date: August 17, 2016

GYNECOLOGIC
GOG-0213: Amendment 16; version date: September 13, 2016

OTHER PROTOCOL NOTICES
BREAST
NSABP B-55/BIG 6-13 ACCRUAL REMINDER!
With Amendment #2 (NCI version date October 19, 2015), the eligibility criteria was changed to include patients with ER and/or PgR positive and HER2 negative breast cancer. There are two B-55 slide sets, available on the CTSU and NRG Oncology websites, which provide an overview of the current protocol. As a result of this amendment, accrual to B-55 is anticipated to increase for both the TNBC and hormone receptor-positive patients. If you have questions regarding patient eligibility or other clinical questions, please contact the Clinical Coordinating Department at 1-800-477-7227 or ccdPGH@NRGOncology.org.

GENITOURINARY
RTOG 9408: Statistical analyses for long-term follow-up is being planned. Please help to ensure we can analyze the data as planned. Please see the memo here for further details.

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, and NRG-CC003. Space is limited so register now and reserve your seat. The next webinar training is scheduled for October 19, 2016.

DRUG SAFETY UPDATES
Safety updates have been issued for GOG legacy studies. For details, please see the GOG Weekly Mailing page.

Safety updates have been issued for NSABP legacy studies. For details, please see the NSABP E-mail Distributions page and the CTSU website.

Safety updates have been issued for RTOG legacy studies. For details, please see the RTOG General Broadcast page.

Safety updates have been issued for the following NRG Oncology studies:

Nivolumab: NRG-GY002, NRG-GY003, NRG-BN002

For NRG-GY002 and NRG-GY003 safety reports, please see the protocol page on the NRG Oncology website for details.

For NRG-BN002 safety reports, please see the RTOG General Broadcast page for details.

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

JOURNAL ARTICLES
Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, Tian D, Vogelbaum MA, Wang TJ, Penas-Prado M, Youssef E, Blumenthal DT, Zhang P, Mehta MP, Barnholtz-Sloan JS. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro Oncol. 2016 Sep 23. pii: now208. [Epub ahead of print] PubMed PMID: 27663387. Read more

MEETING ABSTRACTS
Accepted for presentation at the
Society for Neuro-Oncology (SNO) meeting November 17-20, 2016
Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty A, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary J, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP, Chakravarti A. MGMT status predicts survival outcomes in NRG Oncology/RTOG 0424: a phase II trial of temozolomide-based chemoradiotherapy for high risk low-grade gliomas.

Peereboom DM, Moughan J, Kim I, De Los Santos JF, Sperduto PW, White JR, Mehta MP. NRG oncology RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain metastasis from Her2-positive breast cancer: A collaborative study of NRG and KROG.

Vera-Bolanos E, Scheurer M, Zhou R, Gilbert MR, Bondy ML, Sulman EP, Yuan Y, Liu Y, Wendland MM, Brachman DG, Bearden JD III, McGovern SL, Wilson SS, Judy KD, Robins HI, Hunter GK, Crocker IR, Chao ST, Kaluza V, Pugh SL, Armstrong TS. Occurrence and implications of myelosuppression during concurrent therapy on NRG Oncology RTOG 0825.

PUBLICATIONS REMINDERS
Please note the following upcoming meeting and abstract submission deadline dates.

Upcoming Meetings
Cochrane Colloquium; Oct 23-27, 2016; Seoul, South Korea

European Society for Medical Oncology (ESMO); Oct 7-11, 2016; Copenhagen, Denmark

International Gynecologic Cancer Society (IGCS); Oct 29-31, 2016; Lisbon, Portugal

International Society for Quality of Life Research (ISOQOL); Oct 19-22, 2016; Copenhagen, Denmark

PA Breast Cancer Coalition (PBCC); Oct 10, 2016; Harrisburg, PA

Upcoming abstract submission deadlines
American Association of Medical Dosimetrists (AAMD); Jun 10-15, 2017; Indianapolis, IN; due to publications committee Oct 17, 2016; meeting abstracts submission deadline Oct 31, 2016; deadline for posters 3-15-17

American Association of Neurological Surgeons (AANS); Apr 22-26, 2017; Los Angeles, CA; due to publications committee Oct 11, 2016; meeting abstracts submission deadline Oct 25, 2016

American Association for Thoracic Surgery (AATS); Apr 29-May 3, 2017; Boston, MA; due to publications committee Oct 3, 2016; meeting abstracts submission deadline Oct 17, 2016

American Society of Clinical Oncology (ASCO) GU; Feb 16-18, 2017; Orlando, FL; due to publications committee Oct 11, 2016; meeting abstracts submission deadline Oct 25, 2016

Inaugural Meeting ASCO/Society for Immunotherapy of Cancer (SITC); Feb 23-25, 2017; Orlando, FL; due to publications committee Oct 4, 2016; meeting abstracts submission deadline Oct 18, 2016

European Society for Radiotherapy and Oncology (ESTRO); May 5-9, 2017; Vienna, Austria; due to publications committee Oct 10, 2016; meeting abstracts submission deadline Oct 24, 2016

Society of Gynecologic Oncology (SGO); Mar 12-15, 2017; National Harbor, MD; meeting abstracts submission deadline Oct 31, 2016 Global session; Dec 5-Jan 8, 2017 LBA

NRG Oncology is proud to be an active participant of #CancerMoonShot.

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address